Out-of-Hospital Cardiac Arrest: Amiodarone and Lidocaine May Improve Survival Outcomes
There were no significant differences in survival to hospital discharge among the amiodarone, lidocaine, and placebo groups.
After a Department of Justice investigation, the rate of noncompliant implantable cardioverter-defibrillator use significantly decreased in the hospital setting.
More patients in the epinephrine group were alive at 30 days than those in the placebo group, but they had more severe neurologic impairment.
Atropine is a muscarinic antagonist and is indicated for temporary blockage of severe or life threatening muscarinic effects.